GlassScriptPhysician profile
Biny Sam George
NPI 1972101897
$683.72
in general payments reported to CMS, 2019-2025
13 companies · $34.31 in 2025
The $34.31 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $225 · 2023: $230 · 2024: $195 · 2025: $34.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $143.96 | 2022-2024 | Lynparza |
| Glaxosmithkline, LLC. | $140.47 | 2022-2023 | Zejula, Jemperli |
| Medtronic, INC. | $72.67 | 2024 | Interstim |
| Davol INC. | $51.40 | 2023-2024 | Arista Ah Flexitip |
| Seagen INC. | $46.43 | 2023 | Tivdak |
| Shield Therapeutics INC | $43.12 | 2022 | |
| Astellas Pharma US INC | $37.53 | 2024 | Veozah |
| Lilly USA, LLC | $34.31 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $25.99 | 2024 | Lynparza |
| Immunogen, INC. | $24.31 | 2023 | Elahere |
| Eisai INC. | $21.98 | 2023 | |
| Myriad Genetic Laboratories, INC. | $21.47 | 2022 | |
| Clovis Oncology, INC. | $20.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biny George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.